EZH2 Alteration Driven by MicroRNA-524-5p and MicroRNA-324-5p Promotes Cell Proliferation and Temozolomide Resistance in Glioma

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 10

PMID 29221202

Citations 11

Authors

Tongle Zhi

Tianfu Yu

Minhong Pan

Er Nie

Weining Wu

Xiefeng Wang

Ning Liu

Yongping You

Yingyi Wang

Junxia Zhang

Affiliations

Soon will be listed here.

Abstract

Recent data have been shown that EZH2 is a critical oncogene via the repression of tumor suppressor genes in human cancers. In our study, we performed a genome-wide miRNA screen with a bioinformatics analysis to identify EZH2 specific miRNAs. Of these miRNAs, miR-524-5p and miR-324-5p were decreased in glioma tissues, and confered poor prognosis for glioma patients. Upregulation of miR-524-5p and miR-324-5p reduced glioma cell proliferation and increased temozolomide (TMZ) chemosensitivity by targeting EZH2. Importantly, the effection of miR-524-5p and miR-324-5p on cell proliferation and TMZ chemosensitivity in glioma were reversed by expression of EZH2 cDNA. Further, miR-524-5p and miR-324-5p overexpression suppressed glioma growth and prolonged survival in an intracranial xenograft model. Multivariate Cox regression analysis revealed that miR-524-5p was an independent prognostic factor in gliobalstoma patients. Taken together, these data indicate that miRNA-driven EZH2 repression may provide evidence of the molecular mechanism for gliomagenesis and the novel therapeutic targets for glioma.

Citing Articles

The Role of Non-Coding RNAs in Epigenetic Dysregulation in Glioblastoma Development.

Isachesku E, Braicu C, Pirlog R, Kocijancic A, Busuioc C, Pruteanu L Int J Mol Sci. 2023; 24(22).

PMID: 38003512 PMC: 10671451. DOI: 10.3390/ijms242216320.

Multi-Omics Analyses Reveal Mitochondrial Dysfunction Contributing to Temozolomide Resistance in Glioblastoma Cells.

Zhang H, Chen Y, Liu X, Deng H Biomolecules. 2023; 13(9).

PMID: 37759808 PMC: 10526285. DOI: 10.3390/biom13091408.

A review on the role of miRNA-324 in various diseases.

Kadkhoda S, Hussen B, Eslami S, Ghafouri-Fard S Front Genet. 2022; 13:950162.

PMID: 36035118 PMC: 9399342. DOI: 10.3389/fgene.2022.950162.

Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment.

Mafi A, Rahmati A, Babaei Aghdam Z, Salami R, Salami M, Vakili O Cell Mol Biol Lett. 2022; 27(1):65.

PMID: 35922753 PMC: 9347108. DOI: 10.1186/s11658-022-00354-4.

Small RNAs as biomarkers to differentiate benign and malign prostate diseases: An alternative for transrectal punch biopsy of the prostate?.

Markert L, Holdmann J, Klinger C, Kaufmann M, Schork K, Turewicz M PLoS One. 2021; 16(3):e0247930.

PMID: 33760831 PMC: 7990312. DOI: 10.1371/journal.pone.0247930.

References

Kim K, Roberts C . Targeting EZH2 in cancer. Nat Med. 2016; 22(2):128-34. PMC: 4918227. DOI: 10.1038/nm.4036. View

Fan T, Wang H, Xiang P, Liu Y, Li H, Lei B . Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma. Int J Clin Exp Pathol. 2014; 7(10):6662-70. PMC: 4230130. View

Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C . The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2005; 439(7078):871-4. DOI: 10.1038/nature04431. View

Geng J, Li X, Zhou Z, Wu C, Dai M, Bai X . EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer. Cancer Lett. 2015; 359(2):275-87. DOI: 10.1016/j.canlet.2015.01.031. View

Liu F, Gu L, Cao Y, Fan X, Zhang F, Sang M . Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients. Biomarkers. 2015; 21(1):80-90. DOI: 10.3109/1354750X.2015.1118537. View

Wang X, Hu B, Shen H, Zhou H, Xue X, Chen Y . Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis. Biomed Pharmacother. 2015; 75:218-25. DOI: 10.1016/j.biopha.2015.07.038. View

Shou J, Ali-Osman F, Multani A, Pathak S, Fedi P, Srivenugopal K . Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene. 2002; 21(6):878-89. DOI: 10.1038/sj.onc.1205138. View

Xu L, Beckebaum S, Iacob S, Wu G, Kaiser G, Radtke A . MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol. 2013; 60(3):590-8. DOI: 10.1016/j.jhep.2013.10.028. View

Martinez-Fernandez M, Duenas M, Feber A, Segovia C, Garcia-Escudero R, Rubio C . A Polycomb-mir200 loop regulates clinical outcome in bladder cancer. Oncotarget. 2015; 6(39):42258-75. PMC: 4747223. DOI: 10.18632/oncotarget.5546. View

10.

Smits M, Nilsson J, Mir S, Van der Stoop P, Hulleman E, Niers J . miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget. 2011; 1(8):710-20. PMC: 3124376. DOI: 10.18632/oncotarget.205. View

11.

Koumangoye R, Andl T, Taubenslag K, Zilberman S, Taylor C, Loomans H . SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer. 2015; 14:24. PMC: 4374188. DOI: 10.1186/s12943-014-0284-y. View

12.

Zhang Y, Lin C, Liao G, Liu S, Ding J, Tang F . MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2. Oncotarget. 2015; 6(32):32586-601. PMC: 4741714. DOI: 10.18632/oncotarget.5309. View

13.

Hu P, Chu J, Wu Y, Sun L, Lv X, Zhu Y . NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. Oncotarget. 2015; 6(32):32410-25. PMC: 4741702. DOI: 10.18632/oncotarget.5609. View

14.

Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P . Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002; 298(5595):1039-43. DOI: 10.1126/science.1076997. View

15.

Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z . hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008; 1236:185-93. DOI: 10.1016/j.brainres.2008.07.085. View

16.

Lu J, Zhao F, Peng Z, Zhang M, Lin S, Liang B . EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma. Oncotarget. 2014; 5(22):11319-32. PMC: 4294357. DOI: 10.18632/oncotarget.2435. View

17.

Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang K . DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer Lett. 2015; 359(2):198-205. DOI: 10.1016/j.canlet.2015.01.005. View

18.

Gomez-Manzano C, Lemoine M, Hu M, He J, Mitlianga P, Liu T . Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol. 2001; 19(2):359-65. DOI: 10.3892/ijo.19.2.359. View

19.

Zhang J, Chen L, Han L, Shi Z, Zhang J, Pu P . EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. Cancer Lett. 2014; 356(2 Pt B):929-36. DOI: 10.1016/j.canlet.2014.11.003. View

20.

Jiang T, Wang Y, Zhou F, Gao G, Ren S, Zhou C . Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis. Oncotarget. 2015; 7(4):4584-97. PMC: 4826228. DOI: 10.18632/oncotarget.6612. View